Analyst Research Roundup: ToughBuilt Industries, Inc. (TBLT), Abeona Therapeutics Inc. (ABEO)

ToughBuilt Industries, Inc. (NASDAQ:TBLT) tinted gains of +1.29% (+0.02 points) to US$1.57. The volume of 0.54 Million shares climbed down over an trading activity of 1.2 Million shares. EPS ratio determined by looking at last 12 month figures is -2.29. Over the same time span, the stock marked US$5.55 as its best level and the lowest price reached was US$0.82. The corporation has a market cap of US$15.5 Million.

ToughBuilt Industries, Inc. (NASDAQ:TBLT)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 16.06 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Abeona Therapeutics Inc. (NASDAQ:ABEO) is worth US$341.85 Million and has recently fallen -9.96% to US$7.05. The latest exchange of 0.54 Million shares is below its average trading activity of 543.55 Million shares. The day began at US$7.77 but the price moved to US$7.14 at one point during the trading and finally capitulating to a session high of US$7.77. The stock tapped a 52-week high of US$22 while the mean 12-month price target for the shares is US$26.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.25, and a price to sales ratio of 64.5. For the past 5 years, the company’s revenue has grown -28.3%, while the company’s earnings per share has grown 52.1%. With an institutional ownership near 68.7%, it carries an earnings per share ratio of -0.96.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 6 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.89.